News

Sanofi-Aventis has presented its new R&D model project. The model, which aims to transform R&D and increase innovation, is the first step of the group’s new strategy which

Cephalon has submitted a supplemental New Drug Application (sNDA) to FDA for Nuvigil (armodafinil) tablets. It is for the indication of improved wakefulness in patients with excessive sleepiness

Chelsea has reached its target enrollment of 82 patients for Study 302, the first of two pivotal phase-III clinical trials in Chelsea’s registration program of Droxidopa. It is

AstraZeneca has announced that its development partner, Pozen has submitted a New Drug Application (NDA) to the FDA, for VIMOVO (PN400) tablets. PN400 is under investigation for the

BioSante and Cell Genesys have entered into a merger agreement, under which the companies will merge in an all-stock transaction, with BioSante as the surviving company. Under the

Peregrine has completed the patient enrollment in its US Phase I clinical trial, evaluating bavituximab as monotherapy in patients with advanced refractory cancers. The objectives of this multi-center

Novavax has signed initial agreement with Spanish Government to license proprietary, recombinant virus-like-particle (VLP) vaccine technology, to Rovi of Spain. Rovi will use the VLP technology to create

Calixa has initiated a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections (UTI). CXA-101 is a parenteral cephalosporin antibiotic with in-vitro and in-vivo

XenoPort has reported positive preliminary results from a phase-II clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to